Clinicopathological features of elderly patients with hepatitis C virus-related hepatocellular carcinoma

Journal of Gastroenterology

Volumn 43, Issue 7, 2008, Pages 550-557

  Miki, Daiki ^a   Aikata, Hiroshi ^a   Uka, Kiminori ^a   Saneto, Hiromi ^a   Kawaoka, Tomokazu ^a   Azakami, Takahiro ^a   Takaki, Shintaro ^a   Jeong, Soo Cheol ^a   Imamura, Michio ^a   Kawakami, Yoshiiku ^a   Takahashi, Shoichi ^a   Itamoto, Toshiyuki ^a   Asahara, Toshimasa ^a   Arihiro, Koji ^b   Chayama, Kazuaki ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

^b HIROSHIMA UNIVERSITY HOSPITAL   (Japan)

Author keywords

Aging; Elderly patients; Fibrosis; Hepatitis C virus; Hepatocellular carcinoma

Indexed keywords

ALPHA FETOPROTEIN; HEPATITIS C ANTIBODY;

ADULT; AGED; AGING; ALCOHOL CONSUMPTION; ARTICLE; BLOOD TRANSFUSION; CLINICAL FEATURE; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DISEASE ACTIVITY; FEMALE; GERIATRIC PATIENT; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; LATENT PERIOD; LIVER ANGIOGRAPHY; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER FIBROSIS; LIVER SURGERY; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; SEX RATIO; THROMBOCYTE COUNT; VIRUS CARCINOGENESIS;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; FEMALE; HEPATITIS C, CHRONIC; HUMANS; LIVER; LIVER NEOPLASMS; MALE; MIDDLE AGED;

EID: 48449104049     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-008-2194-5     Document Type: Article

References (42)

1. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a bloodborne non-A, non-B viral hepatitis genome. Science 1989;244:359-362.
2. Kuo G, Choo QL, Alter HJ, Gitnick GL, Redeker AG, Purcell RH, et al. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science 1989;244:362-364.
3. Bruix J, Barrera JM, Calvet X, Ercilla G, Costa J, Sanchez-Tapias JM, et al. Prevalence of antibodies to hepatitis C virus in Spanish patients with hepatocellular carcinoma and hepatic cirrhosis. Lancet 1989;2:1004-1006.
4. Colombo M, Kuo G, Choo QL, Donato MF, Del Ninno E, Tommasini MA, et al. Prevalence of antibodies to hepatitis C virus in Italian patients with hepatocellular carcinoma. Lancet 1989;2:1006-1008.
5. Saito I, Miyamura T, Ohbayashi, Harada H, Katayama T, Kikuchi S, et al. Hepatitis C virus infection is associated with the development of hepatocellular carcinoma. Proc Natl Acad Sci USA 1990;87:6547-6549.
6. Hasan F, Jeffers LJ, De Medina M, Reddy KR, Parker T, Schiff ER, et al. Hepatitis C-associated hepatocellular carcinoma. Hepatology 1990;12:589-591.
7. Kew MC, Houghton M, Choo QL, Kuo G. Hepatitis C virus antibodies in Southern African blacks with hepatocellular carcinoma. Lancet 1990;335:873-874.
8. Sbolli G, Zanetti AR, Tanzi E, Cavanna L, Civardi G, Fornari F, et al. Serum antibodies to hepatitis C virus in Italian patients with hepatocellular carcinoma. J Med Virol 1990;30:230-232.
9. Vargas V, Castells L, Esteban JI. High frequency of antibodies to the hepatitis C virus among patients with hepatocellular carcinoma. Ann Intern Med 1990;112:967.
10. Yu MC, Tong MJ, Coursaget P, Ross RK, Govindarajan S, Henderson BE. Prevalence of hepatitis B and C viral markers in black and white patients with hepatocellular carcinoma in the United States. J Natl Cancer Inst 1990;82:1038-1041.
11. Caporaso N, Romano M, Marmo R, de Sio I, Morisco F, Minerva A, et al. Hepatitis C virus infection is an additive risk factor for development of hepatocellular carcinoma in patients with cirrhosis. J Hepatol 1991;12:367-371.
12. Nishioka K, Watanabe J, Furuta S, Tanaka E, Iino S, Suzuki H, et al. A high prevalence of antibody to the hepatitis C virus in patients with hepatocellular carcinoma in Japan. Cancer (Phila) 1991;67:429-433.
13. Liang TJ, Jeffers LJ, Reddy KR, De Medina M, Parker IT, Cheinquer H, et al. Viral pathogenesis of hepatocellular carcinoma in the United States. Hepatology 1993;18:1326-1333.
14. Okuda K. Hepatitis C virus and hepatocellular carcinoma. In: Okuda K, Tabor E, editors. Liver cancer. New York: Churchill Livingstone; 1997. p. 39-50.
15. Ikeda K, Saitoh S, Koide I, Arase Y, Tsubota A, Chayama K, et al. A multivariate analysis of risk factors for hepatocellular carcinogenesis. Hepatology 1993;18:47-53.
16. Chiba T, Matsuzaki Y, Abei M, Shoda J, Aikawa T, Tanaka N, et al. Multivariate analysis of risk factors for hepatocellular carcinoma in patients with hepatitis C virus-related liver cirrhosis. J Gastroenterol 1996;31:552-558.
17. Degos F, Christidis C, Ganne-Carrie N, Farmachidi JP, Degott C, Guettier C, et al. Hepatitis C virus related cirrhosis: Time to occurrence of hepatocellular carcinoma and death. Gut 2000;47:131-136.
18. Aizawa Y, Shibamoto Y, Takagi I, Zeniya M, Toda G. Analysis of factors affecting the appearance of hepatocellular carcinoma in patients with chronic hepatitis C. Cancer (Phila) 2000;89:53-59.
19. Shiratori Y, Ito Y, Yokosuka O, Imazeki F, Nakata R, Tanaka N, et al. Antiviral therapy for cirrhotic hepatitis C: Association with reduced hepatocellular carcinoma development and improved survival. Ann Intern Med 2005;142:105-114.
20. Tsukuma H, Hiyama T, Tanaka S, Nakao M, Yabuuchi T, Kitamura T, et al. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med 1993;328:1797-1801.
21. Yohida H, Shiratori Y, Moriyama M, Arakawa Y, Ide T, Sata M, et al. Interferon therapy reduces the risk for hepatocellular carcinoma. Ann Intern Med 1999;131:174-181.
22. The OBSVIRC, METAVIR, CLINIVIR and DOSVIRC groups, Poynard T, Bedossa P, Oplon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 1997;349:825-832.
23. Poynard T, Ratziu V, Charlotte F, Goodman Z, McHutchison J, Albrecht J. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C. J Hepatol 2001;34:730-739.
24. Ohishi W, Kitamoto M, Aikata H, Kamada K, Kawakami Y, Ishihara H, et al. Impact of aging on the development of hepatocellular carcinoma in patients with hepatitis C virus infection in Japan. Scand J Gastroenterol 2003;8:894-900.
25. Liver cancer study group of Japan. Survey and follow-up study of primary liver cancer in Japan: Report 14. Acta Hepatol Jpn 2000;40:799-811.
26. Hamada H, Yatsuhashi H, Yano K, Daikoku M, Arisawa K, Inoue O, et al. Impact of aging on the development of hepatocellular carcinoma in patients with posttransfusion chronic hepatitis C. Cancer (Phila) 2002;95:331-339.
27. Tanaka N, Chiba T, Matsuzaki Y, Osuga T, Aikawa T, Mitamura K. High prevalence of hepatitis B and C viral markers in Japanese patients with hepatocellular carcinoma. Gastroenterol Jpn 1993;28:547-553.
28. Kasahara A, Hayashi N, Mochizuki K, Takayanagi M, Yoshioka K, Kakumu S, et al. Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Hepatology 1998;27:1394-1402.
29. The Liver Cancer Study Group of Japan. The general rules for the clinical and pathological study of primary liver cancer. Version 4. Tokyo: Kanehara; 2000.
30. Ono E, Shiratori Y, Okudaira T, Imamura M, Teratani T, Kanai F, et al. Platelet count reflects stage of chronic hepatitis C. Hepatol Res 1999;15:192-200.
31. Poynard T, Bedossa P. Age and platelet count: A simple index for predicting the presence of histological lesions in patients with antibodies to hepatitis C virus. J Viral Hepat 1997;4:199-208.
32. Forns X, Ampurdanes S, Lloert JM, Aponte J, Quinto L, Martinez-Bauer E, et al. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology 2002;36:986-992.
33. Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003;38:518-526.
34. Pohl A, Behling C, Oliver D, Kilani M, Monson P, Hassanein T. Serum aminotransferase levels and platelet counts as predictors of degree of fibrosis in chronic hepatitis C virus infection. Am J Gastroenterol 2001;96:3142-3146.
35. Kaul V, Friedenberg FK, Braitman LE, Anis U, Zaeri N, Fazili J, et al. Development and validation of a model to diagnose cirrhosis in patients with hepatitis C. Am J Gastroenterol 2002;97:2623-2628.
36. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis. Diagnosis, grading and staging. Hepatology 1994;19:1513-1520.
37. Silini E, Botteli R, Asti M, Bruno S, Candusso ME, Brambilla S, et al. Hepatitis C virus genotype and risk of hepatocellular carcinoma in cirrhosis. Gastroenterology 1996;111:199-205.
38. Haydon GH, Jarvis LM, Simmonds P, Harrison DJ, Garden OJ, Hayes PC. Association between chronic hepatitis C infection and hepatocellular carcinoma in a Scottish population. Gut 1997;40:128-132.
39. Chiaramonte M, Stroffolini T, Vian A, Stazi MA, Floreani A, Lorenzoni U, et al. Rate of incidence of hepatocellular carcinoma in patients with compensated viral cirrhosis. Cancer (Phila) 1999;85:2132-2137.
40. Benson D, Mitchell N, Dix D. On the role of aging in carcinogenesis. Mutat Res 1996;356:209-216.
41. Aikata H, Takaishi H, Kawakami Y, Takahashi S, Kitamoto M, Nakanishi T, et al. Telomere reduction in human liver tissues with age and chronic inflammation. Exp Cell Res 2000;256:578-582.
42. Isokawa O, Suda T, Aoyagi Y, Kawai H, Yokota T, Takahashi T, et al. Reduction of telomeric repeats as a possible predictor for development of hepatocellular carcinoma. Hepatology 1999;30:408-412.